Zhitong Finance APP learned that Moderna Inc (NASDAQ:)(MRNA.US) announced on Monday that it plans to expand the scale of clinical trials of its new crown vaccine in children aged 5 to 11. The company began clinical trials of its new crown vaccine in children at the end of March this year. The expansion of the trial is to increase the possibility of detecting potential rare side effects, but the company declined to say how many children it ultimately hopes to expand.
Last month, the U.S. Food and Drug Administration (FDA) added a warning about the risk of heart inflammation to the warning message about Moderna and Pfizer’s (PFE.US) new crown vaccine. The FDA announced that the US Centers for Disease Control and Prevention (CDC) report shows that after young people and children are vaccinated with the above two mRNA vaccines, more cases of heart inflammation (myocarditis or pericarditis) will occur.
The company said: “Expanding the test is our intention. We are actively discussing a proposal with the FDA. We expect to obtain FDA approval in the winter of 2021/early 2222.”
Vaccination of children is considered the key to ending the new crown epidemic. Scientists say that the United States is unlikely to achieve herd immunity until children can be vaccinated.
Federal health officials will need to balance the risk of rare side effects that the vaccine may have with the risk of contracting the new coronavirus. In June, US health officials stated that there have been more than 1,200 cases of myocarditis or pericarditis, mainly in people 30 years of age and younger who received injections. Officials said at the time that the combination of Pfizer and Moderna vaccines would only have 12.6 heart inflammation cases per million doses. The benefits of the vaccine still outweigh the risks.
As of Monday’s close, Moderna closed down 3.72 to $335.87; Pfizer closed up 0.31 to $41.81.
Fusion MediaOr anything withFusion MediaThe person concerned does not accept any liability for loss or damage caused by relying on the data, quotations, charts and buy/sell signals contained in this website. Please fully understand the risks and costs associated with financial market transactions. This is one of the most risky forms of investment. The English version of this agreement is the main version. If there is a discrepancy between the English version and the Chinese version, the English version shall prevail.